Development and validation of LC-MS/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients.

Development and validation of LC-MS/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients.

The introduction of imatinib, an oral tyrosine kinase inhibitor, as first-line standard therapy in patients with unresectable, metastatic, or recurrent gastro-intestinal stromal tumor (GIST), strongly improved their treatment outcomes. However, therapeutic drug monitoring (TDM) is recommended for th...

Full description

Bibliographic Details
Main Authors: Valentina Iacuzzi, Bianca Posocco, Martina Zanchetta, Marcella Montico, Elena Marangon, Ariana Soledad Poetto, Mauro Buzzo, Sara Gagno, Angela Buonadonna, Michela Guardascione, Bruno Casetta, Giuseppe Toffoli
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0225225

Internet

https://doi.org/10.1371/journal.pone.0225225

Similar Items